Repligen Corporation
RGEN · Healthcare
$170.02
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
Teva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Repligen (RGEN) reported Q2 2026 adjusted EPS of 54 cents, beating the consensus estimate of 45 cents, with revenues of $204.1 million up 12% year-over-year. The company raised its full-year 2026 revenue guidance to $813-$835 million and EPS guidance to $2.03-$2.09. Stock has gained 27.7% since the earnings report and received a Zacks Rank #1 (Strong Buy) rating.